CiVi Biopharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.civibio.com
Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Civi Biopharma, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04164888
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
- Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo IV infusion
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Civi Biopharma, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT04040322
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of Arizona - Arthritis Research Center, Tucson, Arizona, United States
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
- Conditions
- Raynaud Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo IV infusion
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Civi Biopharma, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03867097
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸Pacific Arthritis Care Center of Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Civi Biopharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03427710
- Locations
- 🇬🇧
Leeds Clinic, Leeds, West Yorkshire, United Kingdom